Xilio Therapeutics (XLO) Change in Receivables (2024 - 2026)

Xilio Therapeutics has disclosed Change in Receivables across 3 years of filings, most recently posting $6.0 million for Q2 2026.

• In Q2 2026, Change in Receivables changed N/A year-over-year to $6.0 million; the TTM figure through Jun 2026 stood at -$11.5 million (changed N/A YoY), while the FY2025 annual figure was $5.0 million, changed N/A from the prior year.
• Change in Receivables came in at $6.0 million for Q2 2026 at Xilio Therapeutics, up from -$5.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $30.0 million in Q1 2024 to a low of -$12.5 million in Q4 2025.
• Average Change in Receivables over 3 years is $4.6 million, with a median of $500000.0 recorded in 2026.